IL101243A
(en)
*
|
1991-03-20 |
1999-12-22 |
Merck & Co Inc |
Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
|
CA2147357A1
(en)
*
|
1992-11-04 |
1994-05-11 |
Nancy M. Gray |
Methods and compositions (+) doxazosin for the treatment of hypertension
|
RU2139053C1
(ru)
*
|
1992-11-04 |
1999-10-10 |
Сепракор, Инк. |
Способ повышения мочеотделения у человека
|
US5294615A
(en)
*
|
1993-04-29 |
1994-03-15 |
Abbott Laboratories |
Terazosin polymorph and pharmaceutical composition
|
US5412095A
(en)
*
|
1993-04-29 |
1995-05-02 |
Abbott Laboratories |
Terazosin monohydrochloride and processes and intermediate for its production
|
US5504207A
(en)
*
|
1994-10-18 |
1996-04-02 |
Abbott Laboratories |
Process and intermediate for the preparation of terazosin hydrochloride dihydrate
|
US5587377A
(en)
*
|
1995-10-24 |
1996-12-24 |
Invamed, Inc. |
Terazosin crystalline polymorph and pharmaceutical compositions thereof
|
JPH11507395A
(ja)
*
|
1995-11-15 |
1999-06-29 |
メルク エンド カンパニー インコーポレーテッド |
アルファ1a アドレナリン受容体拮抗薬
|
DE19546573A1
(de)
*
|
1995-12-13 |
1997-06-19 |
Uetikon Chemie Gmbh |
Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
|
US5952003A
(en)
*
|
1996-08-01 |
1999-09-14 |
Novartis Corporation |
Terazosin capsules
|
US5922722A
(en)
*
|
1996-11-12 |
1999-07-13 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
IT1286789B1
(it)
*
|
1996-11-29 |
1998-07-17 |
Alfa Chem Ital |
Processo per la produzione della forma i del terazosin monocloridato anidro
|
GB9708917D0
(en)
*
|
1997-05-01 |
1997-06-25 |
Pfizer Ltd |
Compounds useful in therapy
|
US6057350A
(en)
*
|
1997-06-18 |
2000-05-02 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6214832B1
(en)
|
1997-06-18 |
2001-04-10 |
Merck & Co., Inc. |
Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
|
US6080760A
(en)
*
|
1997-06-18 |
2000-06-27 |
Merck & Co., Inc. |
Alpha 1A adrenergic receptor antagonists
|
US6376503B1
(en)
|
1997-06-18 |
2002-04-23 |
Merck & Co., Inc |
Alpha 1a adrenergic receptor antagonists
|
US6143750A
(en)
*
|
1997-06-18 |
2000-11-07 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6037354A
(en)
*
|
1997-06-18 |
2000-03-14 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6248888B1
(en)
|
1997-11-14 |
2001-06-19 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of terazosin hydrochloride dihydrate
|
WO2000006565A1
(en)
|
1998-07-30 |
2000-02-10 |
Merck & Co., Inc. |
ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
|
AU1808400A
(en)
|
1998-10-29 |
2000-05-22 |
Merck & Co., Inc. |
Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
|
US6319932B1
(en)
|
1998-11-10 |
2001-11-20 |
Merck & Co., Inc. |
Oxazolidinones useful as alpha 1A adrenoceptor antagonists
|
US6228870B1
(en)
|
1998-11-10 |
2001-05-08 |
Merck & Co., Inc. |
Oxazolidinones useful as alpha 1a adrenoceptor antagonists
|
AU1345600A
(en)
|
1998-11-12 |
2000-06-05 |
Merck & Co., Inc. |
Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
|
DE19861323B4
(de)
*
|
1998-12-08 |
2006-02-16 |
Robert Bosch Gmbh |
Verfahren zur Übertragung von Kurznachrichten
|
DE19856440C2
(de)
*
|
1998-12-08 |
2002-04-04 |
Bosch Gmbh Robert |
Übertragungsrahmen und Funkeinheit mit Übertragungsrahmen
|
US6358959B1
(en)
|
1999-01-26 |
2002-03-19 |
Merck & Co., Inc. |
Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355457A
(en)
|
1999-09-30 |
2001-04-25 |
Merck & Co Inc |
Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355263A
(en)
|
1999-09-30 |
2001-04-18 |
Merck & Co Inc |
Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355456A
(en)
|
1999-09-30 |
2001-04-25 |
Merck & Co Inc |
Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355264A
(en)
|
1999-09-30 |
2001-04-18 |
Merck & Co Inc |
Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
|
US6200573B1
(en)
|
1999-12-03 |
2001-03-13 |
Starcor Pharmaceuticals, Inc. |
Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
|
US6313172B1
(en)
|
2000-04-13 |
2001-11-06 |
Allergan Sales, Inc. |
Methods and compositions for modulating alpha adrenergic receptor activity
|
US7335803B2
(en)
|
2001-10-19 |
2008-02-26 |
Allergan, Inc. |
Methods and compositions for modulating alpha adrenergic receptor activity
|
JP2002121188A
(ja)
*
|
2000-07-18 |
2002-04-23 |
Toray Ind Inc |
ピペラジンアミド化合物の製造法およびピペラジンテトラヒドロフラン−2−カルボン酸アミド誘導体
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
WO2002054996A2
(en)
*
|
2000-10-23 |
2002-07-18 |
Euro Celtique Sa |
Terazosin transdermal device and methods
|
US6534542B2
(en)
|
2001-02-27 |
2003-03-18 |
Allergen Sales, Inc. |
(2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
|
US7323485B2
(en)
|
2002-05-21 |
2008-01-29 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
US7276522B2
(en)
|
2002-05-21 |
2007-10-02 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
US7358269B2
(en)
|
2002-05-21 |
2008-04-15 |
Allergan, Inc. |
2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
|
US7091232B2
(en)
|
2002-05-21 |
2006-08-15 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
JP5165242B2
(ja)
|
2003-09-12 |
2013-03-21 |
アラーガン、インコーポレイテッド |
疼痛およびα2アドレナリン受容体が関与する他の状態の処置のための方法および組成物
|
US7390829B2
(en)
|
2005-06-29 |
2008-06-24 |
Allergan, Inc. |
Alpha-2 adrenergic agonists
|
US7323477B2
(en)
|
2006-02-02 |
2008-01-29 |
Allergan, Inc. |
7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
|
WO2008021891A2
(en)
*
|
2006-08-08 |
2008-02-21 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
|
US7598417B2
(en)
|
2007-04-12 |
2009-10-06 |
Allergan, Inc. |
Substituted fluoroethyl ureas as alpha 2 adrenergic agents
|
DK2155733T3
(da)
|
2007-05-23 |
2012-10-29 |
Allergan Inc |
Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
|
AU2008256928A1
(en)
|
2007-05-23 |
2008-12-04 |
Allergan, Inc. |
Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
|
US7829587B2
(en)
|
2008-01-09 |
2010-11-09 |
Allergan, Inc. |
Substituted 2-aminotetralin derivatives as selective alpha 2B agonist
|
US7902247B2
(en)
|
2008-01-09 |
2011-03-08 |
Allergan, Inc. |
Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
|
WO2009091759A1
(en)
|
2008-01-18 |
2009-07-23 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US8809379B2
(en)
|
2008-01-18 |
2014-08-19 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US20090239918A1
(en)
*
|
2008-03-24 |
2009-09-24 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US8420114B2
(en)
|
2008-04-18 |
2013-04-16 |
Warsaw Orthopedic, Inc. |
Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
|
US9072727B2
(en)
|
2008-04-18 |
2015-07-07 |
Warsaw Orthopedic, Inc. |
Alpha adrenergic receptor agonists for treatment of degenerative disc disease
|
AU2009244536A1
(en)
|
2008-05-05 |
2009-11-12 |
Allergan, Inc. |
Alpha2B and alpha2C agonists
|
EP2285372A2
(de)
|
2008-05-16 |
2011-02-23 |
Allergan, Inc. |
Selektive adrenerge wirkstoffe vom subtyp alpha 2 und verfahren zu ihrer verwendung
|
EP2370430B1
(de)
|
2008-12-08 |
2014-06-04 |
Allergan, Inc. |
N-(1-phenyl-2-arylethyl)-4,5-dihydro-3h-pyrrol-2-aminverbindungen als untertypselektive modulatoren von alpha2b- oder alpha2b- und alpha2c-adrenoceptoren
|
AU2010210513A1
(en)
|
2009-02-06 |
2011-09-01 |
Allergan, Inc. |
Pyridine compounds as subtype selective modulators of alpha2B and/or alpha 2C adrenergic receptors
|
US8329918B2
(en)
|
2009-07-30 |
2012-12-11 |
Allergan Inc. |
Selective alpha 2B/2C agonists
|
EP2486009B1
(de)
|
2009-10-06 |
2019-08-21 |
Allergan, Inc. |
2h-pyrrol-5-aminderivate als alpha adrenorezeptormodulatoren
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
US11224572B1
(en)
*
|
2020-08-17 |
2022-01-18 |
Novitium Pharma LLC |
Stable oral liquid composition of terazosin
|